Metropolitan Life Insurance Company (MetLife)’s Fennec Pharmaceuticals FENC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,003	Closed	-$11.2K	–	756
2024 Q1	$11.2K	Hold	1,003	–	–	﹤0.01%	2095
2023 Q4	$11.3K	Hold	1,003	–	–	﹤0.01%	2145
2023 Q3	$7.53K	Hold	1,003	–	–	﹤0.01%	2332
2023 Q2	$8.86K	Buy	+1,003	New	+$8.34K	﹤0.01%	2363
2020 Q3	–	Sell	-7,824	Closed	-$65.3K	–	2574
2020 Q2	$65.3K	Buy	+7,824	New	+$58.2K	﹤0.01%	2463

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FENC Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Fennec Pharmaceuticals (FENC) in Q2 2024, closing a stake of 1,003 shares — an estimated $11.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FENC in Q2 2020 and held it in 5 quarters. The position peaked at $65.3K in Q2 2020. 64 funds tracked by Wall St. Rank hold FENC as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Fennec Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,003 Fennec Pharmaceuticals shares in Q2 2024, an estimated $11.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Fennec Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Fennec Pharmaceuticals position peaked at $65.3K in Q2 2020.
64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.